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Objective. Skin damage caused by chronic venous disease (CVD) is associated with severe microangiopathic changes in the
skin. The aim was to determine whether patients in various CEAP clinical stages of CVD have elevated plasma levels of
VEGF compared to controls and whether this correlates with the symptoms.
Methods. One hundred and eight patients with CVD attending the vascular clinic were included and assigned to the
appropriate CEAP clinical stage. Thirty healthy control subjects were also included. Patients and controls were studied after
resting supine for 10 min. Blood samples were taken from a dorsal foot vein. Assay of VEGF was performed with an enzyme-
linked immunosorbent assay. Volunteers’ symptoms were recorded using a visual analogue scale (VAS) for heaviness,
cramps, paraesthesiae and swelling.
Results. Plasma levels of VEGF were: control ðn30Þ median VEGF 56 pg/ml (inter-quartile range IQR 38–85), CEAP C2
(varicose veins) 86 (39–133), C5 (healed ulcer) 88 (67–135). Median difference: control vs. C5 33 (95% confidence interval
(CI) 8–61). Median differences were calculated using the Wilcoxon method.
VEGF level in patients with VAS swelling score ¼ 0:54 pg/ml (IQR 31–104). VEGF level in patients with VAS swelling
score .0:85 pg/ml (IQR 40–147). Difference between medians: 20 ng/ml, 95% CI for the median difference: (5–44). No
differences were observed for symptoms of heaviness, cramps or paraesthesiae.
Conclusion. There was a trend towards raised VEGF in all stages of CVD, but this only reached statistical significance in
those with healed ulceration. The symptom of swelling was associated with raised VEGF levels; however, the symptoms of
heaviness, cramps, and paraesthesiae were not associated with raised VEGF levels.
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Introduction
Venous valvular incompetence of lower limb veins
leads to chronic venous disease (CVD). This may result
in symptoms varying from uncomplicated varicose
veins to oedema, liposclerotic skin changes and
ulceration. These symptoms occur in between 31 and
11% of the population.2 Venous disease of the legs
affects up to 9% of the total population, a risk that
increases with age and occurs with equal prevalence in
men and women, according to a carefully conducted
epidemiological study.3
Several theories concerning the pathogenesis of
venous ulcers have been proposed. The most recent
one suggests that leucocytes, which accumulate in the
microcirculation during venous hypertension, become
activated releasing toxic metabolites, proteolytic
enzymes and free radicals.4 Several studies implicate
inappropriate neutrophil activation as the most likely
mechanism of tissue damage in this disease.5,6 The full
sequence of events resulting in venous ulceration still
remains unclear.
Skin damage caused by chronic venous insuffi-
ciency is associated with severe microangiopathic
changes in the skin. This was first recognized
histologically by Burnand et al.7 Normal skin has
occasional capillaries on histologic sections, and the
number of capillaries does not increase among
patients with varicose veins. Microscopic examination
of the capillaries has been used to study the micro-
circulation of the skin in the presence of venous
disease.8 The microangiopathy in CVD is character-
ised by the presence of enlarged, dilated, coiled and
ramified capillaries, which are surrounded by an
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enlarged pericapillary spaces (halos)9 and reduced
capillary numbers, microvascular thrombosis, oblit-
erations and increased permeability of microlympha-
tics10 depending on the severity of the CVD.
The proliferation of the capillary endothelium has
not been fully explained, although production of
vascular endothelial growth factor (VEGF) in the
epidermis has been demonstrated.11 A possible expla-
nation of the microangiopathic changes is that VEGF
reaches the main capillaries in the underlying papil-
lary dermis and causes them to proliferate. Many
growth factors have been identified that might be
responsible for the angiogenic response in CVD.12,13
The aim of our study was to measure the basal
plasma VEGF levels among control subjects and
different CEAP (Clinico Etiologic Anatomic Patho-
logic)14 stages of patients with chronic venous. We also
wished to explore the relationship between symptoms
attributable to venous disease and VEGF.
Materials and Methods
Patients considered for the entry into the study were
those of attending The Middlesex Hospital Outpatient
for the management of venous disease. Those suitable
for the inclusion in the study were canvassed by a
letter of explanation indicating the nature of the study.
Patients with CEAP clinical class C2 (varicose veins),
C3 (oedema), C4 (skin changes) and C5 (healed ulcer)
were considered. Thirty normal healthy volunteers
acted as control subjects (CO). This group comprised
of the members of the department of Surgery and
Haematology, patients treated for unrelated con-
ditions at The London Foot Hospital and normal
healthy volunteers from the general public. They had
no symptoms or signs of arterial or venous disease of
the lower limb.
The inclusion criteria for the study were patients of
C2–C5 stage of CEAP clinical stage of CVD from
either sex, age above 18 years old and of any race.
Exclusion criteria have been shown in Table 1.
Patients and volunteers fulfilling the entry criteria
and giving informed written consent were studied
further. Approval for the study was obtained from
UCL Medical School Committee for medical ethics.
Thirty normal volunteers (13M:17F, median age 53
years, range 47–56 years) and 108 patients (47M:61F,
median age 53 years, range 44–61 years) with CVD
were studied.
All patients were assessed clinically by a vascular
surgeon skilled in the management of venous diseases
to determine the clinical grade of the CEAP classifi-
cation. A medical history was taken and clinical
examination was performed. This included a systemic
as well as venous examination. All patients had a full
blood count, serum urea and electrolytes and liver
function tests. Patients included in the study under-
went standard vascular laboratory investigation, as
part of their routine management for venous disease,
including duplex ultrasonography and measurement
of photoplethysmography venous refilling times. The
numbers of patients and controls studied and their age
and sex distribution including their duplex findings in
various groups of CEAP are summarised in Table 2.
Procedure
The study was conducted in an environmental
chamber at 22 8C. All the patients and control subjects
were acclimatised for 10–20 min, whilst lying supine
before the start of the experimental protocol to
minimize venous pressure in the leg. A 23-gauge
canula (Venisystemse Butterflyw, Abbott, Ireland) was
placed in the distal long saphenous vein or dorsal foot
vein of the most affected leg. Blood was collected into
EDTA tubes and plasma was separated by centrifu-
gation. Samples were frozen at284 8C before analysis.
Assay of VEGF165 protein was performed by commer-
cially available ELISA kits manufactured by R&D
Systems Europe, UK, once all samples were collected.
Table 1. Exclusion criteria.
Diabetes mellitus
Connective tissue disorders including rheumatoid arthritis
Blood disorders
Arterial disease (ankle-brachial index , 0.9)
Impaired hepatic function (ALAT or ASAT
3 £ upper limit)
Impaired renal function (serum creatinine . 120 mmol/l)
Any concomitant active disease or abnormality
in laboratory test
Infection within the previous 6 weeks
Patient with concomitant acute or chronic
disease that may interfere with the
results (particularly inflammatory and/or infectious disease)
Recent deep venous thrombosis (less than
1 year)
Recent superficial venous thrombosis (less than
15 days)
Pregnant or breastfeeding women
Excluded medications
Non steroidal anti-inflammatory drugs, Salicylates
Corticoids; Vit A, Vit C, Vit
E and derivatives
Pentoxyfilline, Naftidrofuryl
Any kind of anticoagulant treatment
Any medication known to alter white
blood cell activity
Any venotropic drugs treatment for 15
days prior to inclusion into and
duration of the study
Sclerotherapy, stripping or any surgery for
varicose veins in previous 3 months
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The symptoms of venous insufficiency (pain,
cramps, heaviness, paraesthesiae and swelling) were
assessed by the investigator with the patient using a
visual analogue scale (VAS of 10 cm). Scale was
marked 0–10 cm, severe symptoms were graded 10,
where absence of symptoms were marked as 0.
Patients were asked to place a vertical mark on a
10 cm horizontal line marked with ‘no symptoms’ at
one end and ‘maximum symptoms’ at the other end.
This was only done for the patients not for the
controls as the controls were selected on the basis of
absence of symptoms and visible varicose veins (CO).
Analysis of data
The difference between medians and 95% CI were
calculated using the Wilcoxon method. All results are
described as median (interquartile range, IQR).
Results
One hundred and thirty-two patients were screened
for the study and 24 patients were excluded on the
basis of the exclusion criteria mentioned in Table 1.
The subjects in each of the groups were of similar
age and sex distribution. The number of patients with
the superficial and the deep venous incompetence
among the study groups and the demographic details
on subjects included are shown in Table 2.
The median plasma VEGF165 levels (pg/ml) for
patients were higher (85 pg/ml) than controls
(56 pg/ml) and has been shown in Table 3. The
median value for our control subjects (56 pg/ml
lying supine) is very close to the data provided by
the manufacturers of the ELISA kit (R&D Systems)
who quote a median value of 62 pg/ml for control
subjects.
Fig. 1 shows that plasma levels of VEGF were
higher among various groups of patients than con-
trols, but statistical significance was only reached in
the C5 group compared to controls. This was probably
due to the wide scatter of data. The levels of VEGF
were approximately 60% higher for the patient groups
than for the control group.
The association of symptoms with plasma VEGF has
been investigated in the patient group and the results
shown in Table 4. The symptom data was separated into
upper and lower halves for each symptom and the
median VAS score calculated for each group. Fourth
column of Table 4, shows that this has resulted in groups
of patients with substantially different symptoms. The
fifth column shows the corresponding plasma VEGF
levels. For the symptoms of heaviness, cramps and
paraesthesiae no statistically significant different differ-
ence was found between patients with few symptoms
and those with most symptoms. However, for the
symptom of oedema the symptomatic patients had
significantly elevated plasma VEGF levels. This out-
come may simply have occurred by chance. To
investigate the relationship between symptoms and
VEGF levels, Pearson’s correlation coefficient ðrÞhas also
been calculated for symptoms measured by the VAS and
the corresponding plasma VEGF levels. The result is
shown in the sixth column of Table 4. The value of this is
universally low, confirming the lack of correlation
between symptoms and biological markers.
Table 2. Distribution of subjects according to age, sex and clinical, etiologic, anatomic, pathologic (CEAP) stage. Duplex findings are also
shown.
Stage and number Sex
distribution
Age (years,
mean value
and range)
No. with
superficial
venous
insufficiency
No. with
deep and
superficial
venous
insufficiency
Controls ðn ¼ 30Þ 13M, 17F 53 (47–56)
Patients ðn ¼ 108Þ 47M, 61F 53 (44–61) 72 þ (6)* 29
C2, C3 ðn ¼ 63Þ 16M, 47F 51 (41–58) 46 þ (3)* 14
C2 ðn ¼ 47Þ 13M, 34F 52 (43–59) 34 þ (2)* 11
C3 ðn ¼ 16Þ 3M, 13F 50 (41–55) 12 þ (1)* 3
C4, C5 ðn ¼ 45Þ 31M, 14F 54 (44–64) 26 þ (3)* 15
C4 ðn ¼ 29Þ 20M, 9F 55 (49–66) 16 þ (2)* 10
C5 ðn ¼ 16Þ 11M, 5F 47 (43–62) 10 þ (1)* 5
*Deep vein not visualised are in parenthesis.
Table 3. Values of basal resting plasma VEGF in patients of chronic
venous disease, expressed as Median (interquartile range, IQR,
ranges in parenthesis) pg/ml. Median difference with controls and
95% confidence interval are also shown.
CEAP stage Controls
(n ¼ 30)
All patients
(n ¼ 108)
Plasma VEGF pg/ml (IQR) 56 (38–85) 85 (49–127)
Median difference vs. controls
(95% CI)
27 (6–48)
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Discussion
Previous studies on VEGF have been reported on
limited numbers of patients. In this investigation, a
substantial number of patients (108) have been
investigated and compared to 30 control subjects.
This greatly increased patient cohort ensured that our
measurements are reliable when considering that, in
venous disease, relatively small changes of inflamma-
tory mediator levels have been sought. We took
considerable care to exclude any patient from the
study where any disease process or medication may
have interfered with the measurements. A further
factor which may confound studies of this type is the
tendency for age differences to arise between patients
with varicose veins (C2) and those with skin changes
and healed ulcers (C4, C5). In this cohort of patients,
the age of the control and patients groups is very
similar.
In our study, there was a trend towards higher
levels of VEGF in all patients groups than in controls,
but this only achieved statistical significance in the C5
patients, due to the large scatter of the data. The levels
of VEGF among patients are similar to those with skin
changes (C4, C5) as those without skin changes (C2,
C3). While it is thought that VEGF may contribute to
the capillary proliferation seen in advanced CVD,15 it
is not clear whether it is hypoxia induced or directly
related to capillary proliferation or both. Therefore,
‘cause and effect’ could not be established with this
study. It is also known that the capillary density is
reduced in advanced forms of CVD (C4, C5), although
capillary convolution and proliferation are prominent
features.16,17 Cutaneous capillary proliferation may
either be in response to hypoxia via VEGF pathway or
some other unknown mechanisms. The trend towards
elevated VEGF levels seen in the C2 and C3 patients is
unlikely to reflect capillary proliferation in the skin,
since this is not normally a feature of uncomplicated
venous disease. It remains to be explored whether this
raised VEGF in C2 CVD is due to increased capillary
density seen in fluorescein microscopy, or in C3 CVD
due to oedema where VEGF acts as permeability factor
or in C4, C5 CVD as part of reparative process as
evidenced by capillary proliferation. In fact, the
explanation for this observation remains unclear,
while the origin of VEGF measured in patients from
the C5 group is also unknown. If it is epidermal origin
then it may contribute to skin damage via VEGF-NO
pathway or it may simply be a response to local
reparative and increased angiogenic process or act
simply as vascular permeability factor. In our previous
study, similarly increased total plasma NO in all
disease groups had been shown, which did reach a
statistically significant level.18
Correlation of symptoms with VEGF was also
investigated in this study. This was done because it
Fig. 1. Graph showing values of VEGF in plasma of control
subjects and patients with CEAP stages (C2–C5) (median
values and interquartile range). Median difference with
confidence interval shown is between C0 and C5.
Table 4. Association of symptoms (score in VAS in cm) with VEGF in patients with various CEAP stages of CVD. All values are expressed
as in median (Interquartile range, IQR, in parenthesis) symptoms in cm and VEGF in pg/ml. Number of patients and their age ranges
have also been shown in each group studied.
Symptoms Age distribution Number in asymptomatic
vs. symptomatic group
Severity distribution in
VAS
Values in asymptomatic
vs. symptomatic
Correlation
coefficient
Heaviness 57 (48–69) vs. 52 (42–59) n ¼ 66 in each group 0 (0–0.2) vs. 5 (3.5–6.4) 61 (35–111) vs.
78 (35–126)
0.01
Cramps 53 (41–61) vs. 54 (47–65) n ¼ 66 in each group 0 (0–0.5) vs. 6.5 (4.4–8.5) 57 (34–116) vs.
72 (38–123)
0.1
Paraesthesiae 54 (47–64) vs. 53 (43–64) n ¼ 71 in asymptomatic
and 61 in symptomatic
group
0 (0–0) vs. 3.1 (0.7–5) 79 (43–124) vs.
51 (31–111)
0.1
Oedema 55 (44–66) vs. 53 (46–63) n ¼ 70 in asymptomatic
and 64 in symptomatic
group
0 (0–0) vs. 5 (2.5–6) 54* (31–104) vs.
85 (40–147)
0.2
*Difference between medians: 21, 95% CI for the median difference: (5–44).
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has been observed that there is a poor correlation
between the severity of physiological abnormality of
the venous system and the resulting symptoms. We
observed higher plasma levels of VEGF in patients
with the higher range of the ‘oedema’ symptom.
Further investigation of the correlation between
symptoms and plasma VEGF levels showed that
there was no consistent relationship.
The data from this study show that all groups of
patients had similar elevations in plasma VEGF level
compared with controls. This may reflect the fact that
this growth factor is induced in patients with venous
disease to repair tissue damage caused by venous
hypertension. However, measurement of plasma
levels may not reliably reflect the actual tissue levels
expressed in the region of tissue repair. It is unlikely
that VEGF as reflected by these plasma levels is an
important factor in explaining the differences between
C3 and C4 patients.
Epidermally derived VEGF is likely to be a factor
in the angiogenesis of lipodermatosclerosis. This
increased expression of VEGF is seen even before
any skin changes develop. We found increased serum
levels of VEGF in our study with patients with venous
disease. In our study, the changes in serum levels were
actually more prominent among the group with C3
disease. Studies that measure the expression of VEGF
mRNA levels might more conclusively prove the
actual site of origin of the protein.
Conclusions
The was a trend to increased plasma VEGF levels in all
groups of patients, but only patients with healed
ulcers (C5) showed statistically raised VEGF levels.
This may reflect the fact that this growth factor is
induced in patients with venous disease to repair
tissue damage caused by CVD. No consistent relation-
ship was found between symptoms recorded by VAS
and plasma levels of VEGF.
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